TUCSON, Ariz., March 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter and year ended December 31, 2017 after the market close on Thursday, March 22. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
Conference Call & Webcast Details
Date: Thursday, March 22
Time: 4:30pm Eastern Time
Toll Free: 800-239-9838
Conference ID: 7843064
HTG Molecular Diagnostics Inc. (“HTG”) is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use our technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
LifeSci Advisors, LLC
HTG Molecular Diagnostics